Computer-aided technique for automatic determination of the relationship between transglottal pressure change and voice fundamental frequency.

OBJECTIVES: The effect of artificially altered transglottal pressures on the voice fundamental frequency (F0) is known to be associated with vocal fold stiffness. Its measurement, though useful as a potential diagnostic tool for noncontact assessment of vocal fold stiffness, often requires manual and painstaking determination of an unstable F0 of voice. Here, we provide a computer-aided technique that enables one to carry out the determination easily and accurately. METHODS: Human subjects vocalized in accordance with a series of reference sounds from a speaker controlled by a computer. Transglottal pressures were altered by means of a valve embedded in a mouthpiece. Time-varying vocal F0 was extracted, without manual procedures, from a specific range of the voice spectrum determined on the basis of the controlled reference sounds. RESULTS: The validity of the proposed technique was assessed for 11 healthy subjects. Fluctuating voice F0 was tracked automatically during experiments, providing the relationship between transglottal pressure change and F0 on the computer. CONCLUSIONS: The proposed technique overcomes the difficulty in automatic determination of the voice F0, which tends to be transient both in normal voice and in some types of pathological voice.

Twenty-six week carcinogenicity study of ampicillin in CB6F1-TgrasH2 mice.

As a part of the ILSI-HESI Alternative to Carcinogenicity Testing (ACT) program, we performed a 26-week carcinogenetic study of nonmutagenic drug, ampicillin (ABPC) in Tg-rasH2 mice. ABPC was given to Tg-rasH2 mice (0, 350, 1000, 3000 mg/kg, p.o.) and Non-Tg mice (0, 3000 mg/kg, p.o.) daily for 26 weeks. As a positive control, a single dose of MNU was administered once to Tg-rasH2 mice (75 mg/kg, i.p.). In this study, Tg-rasH2 mice did not demonstrate any increases in tumor development in response to ABPC. Thus, ABPC had no carcinogenicity in the 26-week carcinogenesis study in Tg-rasH2 mice or in a 2-year carcinogenesis study in B6C3F1 mice.